Close Menu

NEW YORK – Investment bank Oppenheimer on Wednesday initiated coverage on diagnostics company Bionano Genomics with a rating of Outperform and a price target of $1.50.

In a note to investors, analyst Kevin DeGeeter said the company is transitioning from selling optical mapping equipment to research labs to selling clinical diagnostics that have the potential to replace microarrays for cytogenetics analysis.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.